Lipoprotein(a). Its importance as an additional atherosclerosis marker.
Autor(a) principal: | |
---|---|
Data de Publicação: | 1997 |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2374 |
Resumo: | Lipoprotein(a) is one of the best examples of heterogeneity of lipoproteins. It presents pre-beta electrophoretic mobility in agarose gel, similar to Very Low Density Lipoproteins, it is found in High Density Lipoproteins due to its hydrated density greater than 1,063 and resembles Low Density Lipoproteins in its size and lipid composition. However, Lp(a) is unique in that it contains an additional distinct antigen, the apo(a), attached to apoB100 by one disulphide bridge. The apo(a)-glycoprotein has recently been shown to have a striking amino acid sequence homology with plasminogen; Lp(a) seems to be a potential bridge between atherosclerosis and thrombosis fields and interest in Lp(a) has greatly increased since then. The new knowledge on the structure of Lp(a) being more and more rapidly acquired should facilitate our understanding of the mechanisms of its atherogenicity and its physiopathological role. Metabolic studies have made it clear that Lp(a) is not a product derived from other apoB-containing lipoproteins, but is secreted by the liver as a distinct mature lipoprotein. Concerning the immunological techniques available to assay Lp(a) they need to be standardized and it is still necessary to define what is meant by the pathological threshold for Lp(a), which will certainly depend on the choice of the standard antiserum and immunological method used. |
id |
RCAP_b5f7524fe66d5b5cef5008ec821b572a |
---|---|
oai_identifier_str |
oai:ojs.www.actamedicaportuguesa.com:article/2374 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Lipoprotein(a). Its importance as an additional atherosclerosis marker.Lipoproteina (a). Sua importância como marcador adicional de aterosclerose.Lipoprotein(a) is one of the best examples of heterogeneity of lipoproteins. It presents pre-beta electrophoretic mobility in agarose gel, similar to Very Low Density Lipoproteins, it is found in High Density Lipoproteins due to its hydrated density greater than 1,063 and resembles Low Density Lipoproteins in its size and lipid composition. However, Lp(a) is unique in that it contains an additional distinct antigen, the apo(a), attached to apoB100 by one disulphide bridge. The apo(a)-glycoprotein has recently been shown to have a striking amino acid sequence homology with plasminogen; Lp(a) seems to be a potential bridge between atherosclerosis and thrombosis fields and interest in Lp(a) has greatly increased since then. The new knowledge on the structure of Lp(a) being more and more rapidly acquired should facilitate our understanding of the mechanisms of its atherogenicity and its physiopathological role. Metabolic studies have made it clear that Lp(a) is not a product derived from other apoB-containing lipoproteins, but is secreted by the liver as a distinct mature lipoprotein. Concerning the immunological techniques available to assay Lp(a) they need to be standardized and it is still necessary to define what is meant by the pathological threshold for Lp(a), which will certainly depend on the choice of the standard antiserum and immunological method used.Lipoprotein(a) is one of the best examples of heterogeneity of lipoproteins. It presents pre-beta electrophoretic mobility in agarose gel, similar to Very Low Density Lipoproteins, it is found in High Density Lipoproteins due to its hydrated density greater than 1,063 and resembles Low Density Lipoproteins in its size and lipid composition. However, Lp(a) is unique in that it contains an additional distinct antigen, the apo(a), attached to apoB100 by one disulphide bridge. The apo(a)-glycoprotein has recently been shown to have a striking amino acid sequence homology with plasminogen; Lp(a) seems to be a potential bridge between atherosclerosis and thrombosis fields and interest in Lp(a) has greatly increased since then. The new knowledge on the structure of Lp(a) being more and more rapidly acquired should facilitate our understanding of the mechanisms of its atherogenicity and its physiopathological role. Metabolic studies have made it clear that Lp(a) is not a product derived from other apoB-containing lipoproteins, but is secreted by the liver as a distinct mature lipoprotein. Concerning the immunological techniques available to assay Lp(a) they need to be standardized and it is still necessary to define what is meant by the pathological threshold for Lp(a), which will certainly depend on the choice of the standard antiserum and immunological method used.Ordem dos Médicos1997-01-30info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2374oai:ojs.www.actamedicaportuguesa.com:article/2374Acta Médica Portuguesa; Vol. 10 No. 1 (1997): Janeiro; 87-93Acta Médica Portuguesa; Vol. 10 N.º 1 (1997): Janeiro; 87-931646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2374https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2374/1789Campos, Einfo:eu-repo/semantics/openAccess2022-12-20T11:00:24Zoai:ojs.www.actamedicaportuguesa.com:article/2374Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:17:42.291748Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Lipoprotein(a). Its importance as an additional atherosclerosis marker. Lipoproteina (a). Sua importância como marcador adicional de aterosclerose. |
title |
Lipoprotein(a). Its importance as an additional atherosclerosis marker. |
spellingShingle |
Lipoprotein(a). Its importance as an additional atherosclerosis marker. Campos, E |
title_short |
Lipoprotein(a). Its importance as an additional atherosclerosis marker. |
title_full |
Lipoprotein(a). Its importance as an additional atherosclerosis marker. |
title_fullStr |
Lipoprotein(a). Its importance as an additional atherosclerosis marker. |
title_full_unstemmed |
Lipoprotein(a). Its importance as an additional atherosclerosis marker. |
title_sort |
Lipoprotein(a). Its importance as an additional atherosclerosis marker. |
author |
Campos, E |
author_facet |
Campos, E |
author_role |
author |
dc.contributor.author.fl_str_mv |
Campos, E |
description |
Lipoprotein(a) is one of the best examples of heterogeneity of lipoproteins. It presents pre-beta electrophoretic mobility in agarose gel, similar to Very Low Density Lipoproteins, it is found in High Density Lipoproteins due to its hydrated density greater than 1,063 and resembles Low Density Lipoproteins in its size and lipid composition. However, Lp(a) is unique in that it contains an additional distinct antigen, the apo(a), attached to apoB100 by one disulphide bridge. The apo(a)-glycoprotein has recently been shown to have a striking amino acid sequence homology with plasminogen; Lp(a) seems to be a potential bridge between atherosclerosis and thrombosis fields and interest in Lp(a) has greatly increased since then. The new knowledge on the structure of Lp(a) being more and more rapidly acquired should facilitate our understanding of the mechanisms of its atherogenicity and its physiopathological role. Metabolic studies have made it clear that Lp(a) is not a product derived from other apoB-containing lipoproteins, but is secreted by the liver as a distinct mature lipoprotein. Concerning the immunological techniques available to assay Lp(a) they need to be standardized and it is still necessary to define what is meant by the pathological threshold for Lp(a), which will certainly depend on the choice of the standard antiserum and immunological method used. |
publishDate |
1997 |
dc.date.none.fl_str_mv |
1997-01-30 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2374 oai:ojs.www.actamedicaportuguesa.com:article/2374 |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2374 |
identifier_str_mv |
oai:ojs.www.actamedicaportuguesa.com:article/2374 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2374 https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2374/1789 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Ordem dos Médicos |
publisher.none.fl_str_mv |
Ordem dos Médicos |
dc.source.none.fl_str_mv |
Acta Médica Portuguesa; Vol. 10 No. 1 (1997): Janeiro; 87-93 Acta Médica Portuguesa; Vol. 10 N.º 1 (1997): Janeiro; 87-93 1646-0758 0870-399X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130630053691392 |